普莱柯：公司获得新兽药注册证书

Core Viewpoint - The company, Pulaike (603566.SH), has received a new veterinary drug registration certificate for a combined vaccine effective against Newcastle disease and infectious bronchitis in chickens, which is expected to enhance its product offerings and market competitiveness [1] Group 1: Product Development - The new veterinary drug, "LaSota strain + SZ160 strain" vaccine, has been officially registered as a new veterinary drug as of July 17, 2025 [1] - The SZ160 strain used in the vaccine is a domesticated attenuated strain of the prevalent QX type, characterized by high reproductive performance, safety, rapid immune response, and long-lasting immunity [1] Group 2: Market Impact - The introduction of this product will diversify the company's poultry vaccine portfolio, thereby improving its market competitiveness [1] - The new vaccine is anticipated to provide a new growth point for the company's performance by effectively preventing the currently prevalent infectious bronchitis disease in domestic chickens [1]